Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Real‐World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents

Trial Profile

Real‐World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Oct 2018

At a glance

  • Drugs Valbenazine (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Therapeutic Use
  • Acronyms RE-Kinect
  • Sponsors Neurocrine Biosciences
  • Most Recent Events

    • 23 Oct 2018 According to a Neurocrine Biosciences media release, data will be presented at the 2018 Annual Psych Congress 2018.
    • 23 May 2018 Results (n=656 enrolled; available data of 236 patients) presented at the 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
    • 09 May 2018 Interim data of 15 caregivers presented at the 171st Annual Meeting of the American Psychiatric Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top